Wyeth Plans Tygacil Filing For CAP In 2007
This article was originally published in The Pink Sheet Daily
Executive Summary
Wyeth will move ahead with tigecycline regulatory filing though the antibiotic failed to show superiority to J&J's Levaquin in Phase III trials.
You may also be interested in...
Wyeth’s Tygacil sNDA For Community-Acquired Pneumonia Accepted By FDA
Company tells “The Pink Sheet” DAILY that tigecycline would address needs of patients resistant to other antibiotics, such as J&J’s Levaquin.
Wyeth’s Tygacil sNDA For Community-Acquired Pneumonia Accepted By FDA
Company tells “The Pink Sheet” DAILY that tigecycline would address needs of patients resistant to other antibiotics, such as J&J’s Levaquin.
J&J Submits Ceftobiprole NDA
Novel cephalosporin would be used to treat complicated skin and skin structure infections, including diabetic foot infections.